Deeter Investments
SRPT icon

Deeter Investments’s Sarepta Therapeutics SRPT Stock Holding History

Deeter Investments’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Hold
75,567
– – 0.19% 74
2026
Q1 		$1.64M Hold
75,567
– – 0.18% 72
2025
Q4 		$1.63M Buy
+75,567
New +$1.59M 0.35% 46

Other funds holding SRPT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $13.7B AUM 40.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Deeter Investments's SRPT Position: Q2 2026 in Review

Deeter Investments held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 75,567 shares worth $1.36M. The position accounts for 0.19% of the portfolio, ranked #74.

Deeter Investments first reported a position in SRPT in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.64M in Q1 2026. 326 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Deeter Investments held 75,567 shares of Sarepta Therapeutics worth $1.36M as of Q2 2026.
  • Deeter Investments left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up 0.19% of Deeter Investments's portfolio in Q2 2026, its #74 holding.
  • Deeter Investments first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Deeter Investments's Sarepta Therapeutics position peaked at $1.64M in Q1 2026.
  • 326 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Deeter Investments's 13F filing for Q2 2026, filed 8 Oct 2026.